Target intelligence / Profile preview

Cardiac muscle contractility pathways

Molecular classification
Other (as a pathway/process; individual components may be G protein-coupled receptor, Ion channel, Enzyme, etc.)
01

Overview

“Cardiac muscle contractility pathways" refers to the diverse network of molecular signaling cascades that regulate the contraction strength and timing of heart muscle cells. These pathways coordinate the influx of calcium through voltage-gated calcium channels, the release of calcium from the sarcoplasmic reticulum (via ryanodine receptors), and the interaction of contractile proteins actin and myosin. Key molecular regulators include beta-adrenergic receptors (modulating cyclic AMP and protein kinase A activity), phospholamban/SERCA (regulating calcium reuptake), and troponin (regulating actin-myosin interaction). Many cardiovascular drugs act by modulating specific components of these pathways, ultimately influencing the force or rhythm of cardiac contraction[2][3][4][6]. Due to the pathway-level nature of this term, it is not a single drug target as conventionally defined.

Other names
Cardiac muscle contraction signaling pathwaysCardiac excitation-contraction coupling pathwaysCardiac contractility signaling cascadesMyocardial contractility pathways
02

Mechanism of action

Modulation of intracellular cyclic AMP/cGMP; Alteration of calcium influx/release from sarcoplasmic reticulum; Regulation of beta-adrenergic receptor signaling; Phosphorylation of contractile or regulatory proteins (e.g., troponin, phospholamban)

03

Biological functions

Cardiac muscle contractionExcitation-contraction couplingCalcium homeostasisSignal transduction
04

Disease associations

Cardiovascular diseaseHeart failureCardiomyopathyArrhythmia
05

Safety considerations

Arrhythmia risk with drugs enhancing contractilityMyocardial ischemia or injury with excessive stimulationHeart failure progression (with chronic activation or inhibition)
06

Interacting drugs

Beta-adrenergic receptor agonists/antagonists (e.g., dobutamine, metoprolol)

4 more in the full profile.

07

Biomarkers

Cardiac troponin I, T (as markers of cardiac muscle injury, not direct measurement of contractile pathway activity)

Beyond the preview

Go deeper on Cardiac muscle contractility pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiac muscle contractility pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call